Evidence map›Paper›PMID 30879165›Full record

ArticleApoptosis : an international journal on programmed cell death2019

Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery.

Erin Morgan, John T Gamble, Martin C Pearce, Daniel J Elson, Robert L Tanguay, Siva Kumar Kolluri, Norbert O Reich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. VIPERACS applied materials & interfaces · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Erin MorganDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, CA, USA. emorgan@chem.ucsb.edu.
John T GambleDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Martin C PearceDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Daniel J ElsonDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Robert L TanguayDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Siva Kumar KolluriDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Norbert O ReichDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, CA, USA. reich@chem.ucsb.edu.

Funding

MODE OF ACTION OF ENVIRONMENTAL TOXICANTST32ES007060 · NIEHS · OREGON STATE UNIVERSITY · PI Jamie DeWitt, Siva Kumar Kolluri · 1985 to 2026
$11.6M
The AHR as a Novel Pathway to the Induction of Regulatory T cellsR01ES016651 · NIEHS · OREGON STATE UNIVERSITY · PI KERKVLIET, NANCY I · 2009 to 2017
$3.5M
NIR Light-Activated Nanoparticles for Drug and Gene DeliveryR01EB012637 · NIBIB · UNIVERSITY OF MINNESOTA · PI ZASADZINSKI, JOSEPH ANTHONY · 2011 to 2014
$1.3M
Two-Photon Microscopy for Biomedical ResearchS10RR022585 · NCRR · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI REESE, BENJAMIN E · 2007 to 2007
$500k
American Cancer Society RSG-13-132-01-CDDMedical Research and Material Command W81XWH-08-1-0600Medical Research and Material Command W81XWH-12-1-0069NCRR NIH HHS S10 RR022585NIBIB NIH HHS R01 EB012637NIEHS NIH HHS R01 ES016651NIEHS NIH HHS T32 ES007060NIH HHS 5RO1ES016651NIH HHS R01 EB012637
6 · The paper itself

Abstract

Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalDrug CarriersDrug LiberationDrug Resistance, NeoplasmGoldHumansLaser TherapyLung NeoplasmsNanoshellsOligopeptidesPaclitaxelAntineoplastic AgentsBCL2 protein, humanDrug CarriersGoldOligopeptidesPaclitaxelphenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucineProto-Oncogene Proteins c-bcl-2ApoptosisBcl-2Hollow gold nanoshellsNuBCPPeptide deliveryResistant cancer

Identifiers

PMID30879165
PMCPMC8918063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.